TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'

June 10, 2026 1:37 PM

TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments "SNY stopping riliprubart's MOBILIZE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found